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Summary
 
Langerhans cells (LCs) are dendritic cells (DCs) that are present in the epidermis, bronchi, and
mucosae. Although LCs originate in bone marrow, little is known about their lineage of origin.
In this study, we demonstrate that in vitro LCs may originate from monocytes. Adult periph-
eral blood CD14
 
1
 
 monocytes differentiate into LCs (CD1a
 
1
 
, E-cadherin
 
1
 
, cutaneous lympho-
cyte-associated antigen
 
1
 
, Birbeck granules
 
1
 
, Lag
 
1
 
) in the presence of granulocyte/macrophage
colony-stimulating factor, interleukin 4, and transforming growth factor 
 
b
 
1 (TGF-
 
b
 
1). This
process occurs with virtually no cell proliferation and is not impaired by 30 Gy irradiation.
Selection of monocyte subpopulations is ruled out since monocyte-derived DCs can further
differentiate into LCs. Our data suggest that in vivo LC differentiation may be induced periph-
erally, from a nonproliferating myeloid precursor, i.e., the monocyte, in response to a TGF-
 
b
 
1–rich microenvironment, as found in the skin and epithelia. Therefore, the monocyte may
represent a circulating precursor critical to the immune response in vivo.
ˆ o
ˆ o
ˆ o
 
D
 
endritic cells (DCs) constitute a family of APCs de-
fined by their morphology and their excellent capac-
ity to initiate a primary immune response (1–3). Langer-
hans cells (LCs) are paradigmatic DCs that are present
within epithelial cells in the epidermis, bronchi, and muco-
sae (4). After an antigenic challenge, LCs migrate into the
T cell areas of lymph nodes where they act as professional
APCs (2). Although LCs originate in bone marrow, little is
known about their lineage of origin.
DCs can be generated in vitro from CD34
 
1
 
 cord blood
or bone marrow progenitors in the presence of GM-CSF
and TNF-
 
a
 
 (5–9), as well as from peripheral blood mono-
nuclear cells in the presence of GM-CSF and IL-4 (1, 10–
12). However, LCs represent a discrete population among
DCs, and the current hypothesis is that LCs arise from a
specific precursor distinct from monocyte precursors (7, 9).
Human LCs share CD1a antigen expression with DCs gen-
erated in vitro (1, 7, 10, 11). However, LCs specifically ex-
press the epithelial antigen E-cadherin (13) and the skin
homing antigen (cutaneous lymphocyte-associated antigen,
CLA) (14, 15), both relevant to their unique localization
within epithelial cells, and they exhibit Birbeck granules
(BGs) and their associated Lag antigen (16, 17).
In this context, recent attention has focused on TGF-
 
b
 
1,
 
which is synthesized at high level by epithelial cells, and
whose presence is apparently required for the development
of LCs in vivo (18). We therefore investigated the effects of
TGF-
 
b
 
1 on DC differentiation at the peripheral level.
 
Materials and Methods
 
Media and Reagents.
 
The medium used was RPMI 1640 sup-
plemented with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100
 
m
 
g/ml streptomycin, and 10% heat-inactivated FCS (all from
GIBCO BRL, Gaithersburg, MD). Recombinant human GM-
CSF was provided by Sandoz AG (Bale, Switzerland), recombi-
nant human IL-4 was purchased from Genzyme Corp. (Cam-
bridge, MA), and recombinant human TGF-
 
b
 
1, polyclonal
chicken anti–human TGF-
 
b
 
1 neutralizing antibodies, and con-
trol chicken Ig were all from R&D Systems (Minneapolis, MN).
 
Culture of Peripheral Blood Monocytes.
 
CD14
 
1
 
 monocytes were
isolated from peripheral blood mononuclear cells of healthy vol-
unteers by negative magnetic depletion using hapten-conjugated
CD3, CD7, CD19, CD45RA, CD56, and anti-IgE antibodies
(monocyte isolation kit, MACS; Miltenyi Biotec, Berglsch Glad-
bach, Germany) and a magnetic cell separator (MACS) according
to the manufacturer’s instructions, routinely resulting in 
 
>
 
95%
purity of CD14
 
1
 
 cells.
Cells were cultured in 6- or 24-well tissue culture plates (Co-
star Corp., Cambridge, MA) in fresh complete medium supple-
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mented with 250 ng/ml GM-CSF 
 
1
 
 100 ng/ml IL-4. TGF-
 
b
 
1
was added at the beginning or, in some experiments, at day 2, 4,
or 6 of the culture. At days 2 and 4, half of the medium was re-
moved and an equivalent volume of fresh medium, supplemented
with the above mentioned cytokines, was added.
 
Cell Proliferation and Apoptosis Studies.
 
For immunocytochemi-
cal detection of cell cycle–associated antigens, harvested cells were
cytocentrifugated using a Cytospin 3 device (Shandon SA, Eragny,
France). Slides were air-dried, fixed in acetone, and stained with
anti-Ki67 antibodies (clone Mib-1, IgG1; Immunotech, Marseille,
France) with an avidin-biotin-peroxidase protocol (19) revealed
by 3-3
 
9
 
 diaminobenzidine as chromogen (Vectasin ABC kit,
Vector, CA). [
 
3
 
H]Thymidine (Amersham Life Science, Bucking-
hamshire, UK) incorporation was measured in newly synthesized
DNA over 48 h, using pulses initiated at day 0, 2, or 4 of the culture
with 1 
 
m
 
Ci/well of [
 
3
 
H]thymidine. Cells were then harvested
with a 96-well Harvester (Pharmacia, St. Quentin, France), col-
lected on glass-fiber filter (Pharmacia) and the incorporation of
thymidine was measured with a Beta-plate microscintillation
counter (LKB, Pharmacia). For apoptosis analysis by flow cytom-
etry (20) and cell cycle analysis, 5 
 
3
 
 10
 
5
 
 cells for each point were
resuspended in 500 
 
m
 
l PBS containing 0.1% triton and 50 
 
m
 
g/ml
propidium iodide (PI) (Sigma Chemical Co., St. Louis, MO), and
incubated for 20 min at 37
 
8
 
C. Analysis of the DNA content of 3
 
3
 
 10
 
4
 
 cells was performed immediately using a flow cytometer
FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA) with the Lysis
II software (Becton Dickinson). Allogeneic mixed leukocyte reac-
tion was performed as previously described (1).
 
Flow Cytometry and Cytological and Immunocytological Analysis of
PBMCs and PBMC-derived Cells.
 
For single- and two-color
flow cytometry, 1.5 
 
3
 
 10
 
5
 
 cells were incubated for 30 min at 4
 
8
 
C
in PBS, 2% human AB serum, and 0.01 M NaN
 
3
 
, with FITC-
conjugated CD1a (clone BL1, IgG1; Immunotech), CD80 (IgG1;
Immunotech), CD40 (IgG1; Immunotech), HLA-I (HLA ABC,
IgG2a; Immunotech), HLA-II (IgG1; Becton Dickinson), and/or
PE-conjugated CD14 (Leu-M3, IgG2b; Becton Dickinson) and
CD11b (IgG2a; Becton-Dickinson) mAbs at the appropriate con-
centration, or with control isotype-matched irrelevant mAbs at
the same concentration. After washing, cells were analyzed with a
FACScalibur
 
Ò
 
 (Becton Dickinson) using CellQuest software
(Becton Dickinson). For cytological examination, harvested cells
were processed as described above and stained using the May-
Grunwald-Giemsa technique (RAL, Rieux, France). For immu-
nochemistry, slides were stained with CD1a (BL1, IgG1; Immu-
 
notech), E-cadherin (HECD-1, IgG1; R&D Systems), Lag
(mouse IgG1; gift of Dr F. Furukawa, Hamamastu University,
Hamdacho, Japan), and CLA (HECA-452, rat IgM; gift of Dr.
L.J. Picker, University of Texas, Dallas, TX).
 
Ultrastructural Study.
 
Cells to be processed for electron mi-
croscopy were fixed overnight at 4
 
8
 
C in 2.5% glutaraldehyde
(Sigma Chemical Co.) in 0.1 M cacodylate buffer, pH 7.4, fol-
lowed by postfixation for 1–2 h in 0.1 M cacodylate-buffered 2%
osmium tetraoxide (Merck, Darmstadt, Germany). After dehydra-
tion in a series of graded ethanol and propylene oxide solutions, cells
were embedded in epoxy resin (Epon 812; TAAB, Janning, Vanves,
France). Ultrathin sections were stained with uranyl acetate and
lead citrate and examined with a JEOL.1200 EX2 electron mi-
croscope (JEOL, Croissy sur Seine, France).
 
Results and Discussion
 
DCs with Phenotypic and Ultrastructural Features of LCs Are
Generated from Human Peripheral Blood Monocytes in the Pres-
ence of TGF-
 
b
 
1, GM-CSF, and IL-4.
 
When cultured for
5–7 d in the presence of TGF-
 
b
 
1, GM-CSF, and IL-4,
CD14
 
1
 
 monocytes (
 
>
 
95% pure) generated large numbers
of dendritic shaped cells (70–80% of the initial population).
These cells expressed CD1a, E-cadherin, and CLA (Fig. 1,
 
b
 
, 
 
d
 
, 
 
f
 
, 
 
h
 
, and Table 1). Typical BGs, i.e., tennis racket–like
structures with rodlike profiles, electron-opaque central
lamella, and rounded ends were identified by electron mi-
croscopy in 26–33% of cells in three out of three experi-
ments (Fig. 1 
 
i
 
). Although rods were relatively short as
compared with those observed in some epidermal LCs, 20–
40% of cells stained strongly for the BG-associated Lag an-
tigen, emphasizing that these monocyte-derived cells are
LCs (Fig. 1 
 
j
 
, Table 1). As previously described (1, 10),
monocyte-derived DCs were also generated from the same
monocytes in presence of GM-CSF and IL-4, and ex-
pressed CD1a, but not CLA, BGs or Lag, and only mar-
ginal levels of E-cadherin in 10% of cells (Fig. 1 
 
a
 
, 
 
c
 
, 
 
e
 
, 
 
g
 
,
and Table 1). Both monocyte-derived DCs and LCs were
highly efficient in stimulating proliferation of allogenous
lymphocytes; as few as 50 DCs were sufficient to trigger T
cell proliferation (data not shown). In vivo, among DCs,
 
Table 1.
 
Effects of TGF-
 
b
 
1 on CD1a, E-cadherin, CLA, and Lag Expression
 
day 6
day 0 GM-CSF 
 
1 
 
IL-4
GM-CSF 
 
1 
 
IL-4 
 
1
 
anti–TGF-
 
b
 
GM-CSF 
 
1
 
 IL-4 
 
1
 
TGF-
 
b
 
1
Cell number (
 
3
 
 10
 
5
 
/ml 10 7.225 
 
6
 
 0.6 6.35 
 
6
 
 0.8 7.25 
 
6
 
 0.5
% CD1a-positive cells 
 
6
 
 SD
 
,
 
1 89.25 
 
6
 
 3 91 
 
6
 
 3 93 
 
6
 
 4
% E-cad-positive cells 
 
6
 
 SD
 
,
 
1 11.1 
 
6
 
 6 6.2 
 
6
 
 5 82 
 
6
 
 8
% CLA-positive cells ND
 
,
 
10
 
,
 
10 80–90
% Lag-positive cells 0 0 ND 20–40
Anti–TGF-
 
b
 
1 blocking antibody was used at a concentration (20 
 
m
 
g/ml) that inhibits as high as 10 ng of recombinant TGF-
 
b
 
1. CD1a and E-cad-
herin expressions were determined by flow cytometry analysis; CLA and Lag expressions were determined by immunocytochemistry. Results are the
mean (
 
6
 
SD) of four experiments. 
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CD1a is expressed only by LCs and no equivalent to the in
vitro monocyte-derived DCs has been found. Such mono-
cyte-derived DC may therefore represent an intermediate
level of differentiation between monocytes and LCs.
Monocyte-derived LCs are nonactivated (immature)
LCs since they do not express CD83 and CD86. However,
a 10-fold increase of HLA class II membrane expression, as
well as the induction of CD83 and CD86 expression and
the loss of E-cadherin expression, were observed after addi-
tion of TNF-
 
a and IL-1 (data not shown).
Induction of LC Differentiation Is Dependent on TGF-b1 in
a Dose-dependent Manner. As shown in Fig. 2, increasing
amounts of recombinant TGF-b1 induced increasing E-cad-
herin expression by monocyte-derived LCs. Neutralizing
anti-TGF-b antibodies completely inhibited E-cadherin
expression induced by recombinant TGF-b1, as well as the
low level of spontaneous E-cadherin expression on GM-CSF
1 IL-4 monocyte-derived DCs that could be attributed to
a low level of endogenous active TGF-b1.
LCs Differentiate from Peripheral Blood CD141 Monocytes,
without Progenitor Proliferation or Selection of a Distinct Mono-
cyte Subpopulation. The appearance of LCs in cultures of
purified monocytes correlated with the disappearance of
Figure 1. Cytological, immunocytological, and ultrastructural analysis
of purified monocytes cultured for 6 d in the presence of GM-CSF and
IL-4 alone (a, c, e, and g), or GM-CSF, IL-4, and TGF-b1 (b, d, f, h, i,
and j). May-Grunwald-Giemsa staining (a and b) showed typical large
cells, with round to oval-shaped or coffee-bean nuclei, and a large pale
cytoplasm with cytoplasmic expansions. DCs cultured in the presence of
GM-CSF and IL-4 alone are stained with CD1a (c) but neither E-cad-
herin (e) nor CLA (g). In contrast, cells cultured in presence of TGF-b1,
GM-CSF, and IL-4 are stained with CD1a (d), E-cadherin (f), and CLA
(h). (i) Typical BGs (arrow and inset) were observed in 26–33% of cells. For
both culture conditions, 15 cells were carefully examined in each of three
separate experiments. Original magnification: 312,000; bar represents 0.5
mm. Inset: original magnification: 325,000. (j) 20–40% of cells in GM-
CSF, IL-4, and TGF-b1 supplemented culture displayed strong reactivity
for the Lag antigen. No staining was observed in monocyte-derived DC
cultures in the absence of TGF-b1.
Figure 2. Dose-dependent induction of E-cadherin expression by
TGF-b1, and inhibition of TGF-b1 effects by anti–TGF-b antibodies. In
the absence of exogenously added TGF-b1 (small dotted line), only 11% of
day 6 DCs expressed low levels of E-cadherin. Increasing amounts of
TGF-b1 (0.1 ng/ml, dotted and dashed line, 1 ng/ml, dashed line; 10 ng/ml,
large dotted line) induced increasing expression of E-cadherin. Addition of
anti–TGF-b antibodies (TGF-b1 10 ng/ml 1 anti–TGF-b antibodies 20
mg/ml, solid line) completely abolished the effects of TGF-b1 on E-cad-
herin expression.964 Monocyte-derived Langerhans Cells
the monocytes as judged by cytological and immunophe-
notypic examination. Two-color flow cytometric analysis
showed that on day 2, CD141/CD1a1 cells appeared at the
same time CD141/CD1a2 cells disappeared, whereas at
days 4 and 5, CD142/CD1a1 DCs arose simultaneously to
the disappearance of CD141/CD1a1 cells (data not shown).
LCs and DCs could not have been generated from prolifer-
ating progenitors because CD34 expression at day 0 was
negative, the proliferative rate evaluated by PI incorpora-
tion was <1% of cells on days 2, 4, and 6 of culture, and
Ki67 antibody stained ,5% of cells throughout culture. In
addition, thymidine uptake during 48-h pulses initiated at
day 0, 2, or 4 of culture was very low (,380 cpm, data not
shown) and 30 Gy irradiation did not alter either DC or
LC differentiation from purified monocytes (Fig. 3). Selec-
tion of distinct monocyte subpopulations was also ruled
Figure 3. Differentation of 30
Gy irradiated monocytes. Freshly
purified (.95% CD141) cells
were irradiated (30 Gy), and then
cultured for 6 d with either GM-
CSF and IL-4 alone or GM-CSF,
IL-4, and TGF-b1. Dot plots
represent double immunostaining
with CD1a and CD14 antibod-
ies, histogram plots represent
E-cadherin expression in the ab-
sence (thin line) or presence (thick
line) of TGF-b1. Differentiation
observed was similar to the dif-
ferentiation of unirradiated mono-
cytes. One representative experi-
ment out of three is shown.
Figure 4. Both fresh monocytes and non-Langerhans DCs differentiate toward either DCs or LCs depending on the absence or presence of TGF-b1,
and retrieval of TGF-b1 did not result in loss of the Langerhans phenotype. Dot plots represent double immunostaining with CD1a and CD14 antibodies
at days 0, 6, and 9 of culture; histogram plots represent E-cadherin expression at the same time (thick lines); and thin lines represent isotypic control stain-
ing. Only TGF-b1–supplemented cultures gave rise to E-cadherin1 DCs. Late addition of TGF-b1 in day 6 DC cultures also resulted in expression of
E-cadherin. Removal of TGF-b1 at day 6 did not result in downregulation of E-cadherin expression. Data are representative of six experiments.965 Geissmann et al. Brief Definitive Report
out, since, in addition to low cell mortality throughout the
culture period (trypan blue exclusion <6%) and a low rate
of apoptosis (<5% as measured by PI incorporation),
monocyte derived-DCs obtained in the presence of GM-
CSF and IL-4 could be further induced to differentiate into
E-cadherin1 and CLA1, and Birbeck1 LCs in the presence
of GM-CSF, IL-4, and TGF-b1 (Fig. 4), thus confirming
that LCs and DCs originate from the same population of
CD141 monocytes.
Taken together, these data indicate that TGF-b1, in the
presence of GM-CSF and IL-4, drives in vitro differentia-
tion of human monocytes into dendritic LCs. This suggests
that distinct phenotypes of myeloid DCs may represent dif-
ferent stages of differentiation rather than distinct lineages,
and that, in addition to early precursors, circulating mono-
cytes may be recruited to differentiate into LCs at the pe-
ripheral level, i.e., in mucosae, in response to TGF-b1.
TGF-b1 is synthesized at high levels by keratinocytes and
may play a role in the in situ regulation of the skin-associ-
ated immune system, since it positively regulates the E-cad-
herin ligand CD103, a costimulatory molecule expressed
on intraepithelial T lymphocytes (21, 22). Moreover, the
skin of TGF-b2/2 mice is devoid of LCs (18), whereas ir-
radiated TGF-b1/1 recipient mice when grafted with
TGF-b2/2 bone marrow had donor-origin LCs (23). The
monocyte therefore appears to be a highly plastic cell, and
may represent a multipotent circulating precursor in the
immune and hematopoietic systems in vivo, able to differ-
entiate into macrophages in the presence of M-CSF (11),
osteoclast-like multinucleated giant cells in the presence of
M-CSF and IL-4 (12), and LCs in the presence of GM-
CSF, IL-4, and TGF-b1.
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